2M Clinical joins MassBio in a discussion on clinical trial diversity.

On June 1, 2020, 2M Clinical’s Chief Medical Officer, Regina James, joined the Massachusetts Biotechnology Council (MassBio) for a discussion on why clinical trial diversity is important, how to achieve it, and the impact of COVID19 on virtual trials.

The webinar, hosted by MassBio’s Edie Stringfellow, can be accessed here: https://youtu.be/3cWkchADrRg 

About the author: Joshua Townley